Top Tweets for #CONTACT03
๐ ๐๐ ๐๐๐ญ๐๐ซ ๐๐ ๐๐จ๐๐ฌ๐งโ๐ญ ๐ฐ๐จ๐ซ๐ค ๐ข๐ง ๐๐๐.โจ๐ ๐๐๐๐๐๐๐-๐๐ & ๐๐ข๐๐ข๐ฏ๐จ-๐: โ ๐ง๐จ ๐๐๐๐๐ ๐๐๐ง๐๐๐ข๐ญ, โ ๏ธ ๐ฆ๐จ๐ซ๐ ๐ญ๐จ๐ฑ๐ข๐๐ข๐ญ๐ฒ.โจ๐ง ๐๐ฏ๐ข๐๐๐ง๐๐ > ๐ข๐ง๐ญ๐ฎ๐ข๐ญ๐ข๐จ๐ง.
#RCC #CONTACT03 #TiNivo2โจ#Immunotherapy #EvidenceBasedOncology
#CONTACT03 Subset analysis: Similar cabozantinib response across IO pretreatment types. @crisuarez08 @VHIO joins @TiansterZhang @UTSWMedCenter to discuss on UroToday > Dr. Suรกrez emphasizes that the key takeaway reinforces cabozantinib as an effective second-line option after any immunotherapy combination. #WatchNow > https://t.co/5BM7ihLKOt
#CONTACT03 Subset analysis: Similar cabozantinib response across IO pretreatment types. @crisuarez08 @VHIO joins @TiansterZhang @UTSWMedCenter to discuss on UroToday > Dr. Suรกrez emphasizes that the key takeaway reinforces cabozantinib as an effective second-line option after any immunotherapy combination. #WatchNow > https://t.co/5BM7ihLKOt
#CONTACT03 Subset analysis: Similar cabozantinib response across IO pretreatment types. @crisuarez08 @VHIO joins @TiansterZhang @UTSWMedCenter to discuss on UroToday > Dr. Suรกrez emphasizes that the key takeaway reinforces cabozantinib as an effective second-line option after any immunotherapy combination. #WatchNow > https://t.co/5BM7ihLKOt
Efficacy and safety of second-line cabozantinib +/ atezolizumab for patients with advanced #RCC after progression on immuno-oncology combinations: subgroup analysis of #CONTACT03. Presented by Cristina Suรกrez, MD, PhD @VHIO. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/a3XL49Vacj @ASCO
6/ TiNivo-2: The addition of nivolumab (PD1) to Tivozanib did not result in improved clinical outcomes in patients with #mRCC treated with prior PD1
Results expand on conclusion from #CONTACT03.
Presented #ESMO2024 and published @TheLancet
https://t.co/UVBIEgmZIM
Heated discussion on the role of IO rechallenge in RCC - despite negative #CONTACT03 and #TiNivo2 #UromigosLive24
โthreshold to rechallenge post adjuvant pembro & what time cutoff to use
โrole of CTLA4 salvage
โneed to better understand IO resistance
The one and only @DrChoueiri presenting results from #TiNivo2 #ESMO2024 @myESMO
Paper out @TheLancet : https://t.co/PqyeQ42M4t
Another study after #CONTACT03 showing no benefit of rechallenging with anti-PD-1/PD-L1 after progression on ICI in #mRCC
@OncoAlert @DanaFarberNews
@DrChoueiri @PRNews @TargetedOnc @OncLive @kidneycan @KidneyCancer @Uromigos @motzermd @AlbigesL @tompowles1 @montypal @neerajaiims @DrRanaMcKay @bergsa83 @VincentWenxinXu @BradMcG04 @MikeSerzanMD Thanks, @DrChoueiri, for sharing this! There is a lot for us to learn from this and #CONTACT03 - not only in RCC but we continue to question rechallenging with ICI in almost every solid malignancy. #OncTwitter #gusm #lcsm #gism #bcsm
Beautiful work! Excellent real world confirmation of our observations in #CONTACT03, donโt you think @DrChoueiri? Congrats to @ggebraelmd @maughanonc @neerajaiims @umangtalking & the @huntsmancancer team!
Just in @JournalCancer ๐Pts w/ clear cell mRCC #kidneycancer from real world Flatiron database s/p ICI Rx๐ Similar survival w/ cabo + ICI vs. cabo monoRx aligning w/ #CONTACT03 trial results @urotoday @OncoAlert @huntsmangu @umangtalking @neerajaiims ๐https://t.co/NzsTan9ZF9
Just in @JournalCancer ๐Pts w/ clear cell mRCC #kidneycancer from real world Flatiron database s/p ICI Rx๐ Similar survival w/ cabo + ICI vs. cabo monoRx aligning w/ #CONTACT03 trial results @urotoday @OncoAlert @huntsmangu @umangtalking @neerajaiims ๐https://t.co/NzsTan9ZF9
@ADESAIONCMD presents a practice changing med onc paper โ #CONTACT03 trial for patients with IO refractory #kidneycancer โ superb discussion from @AlbigesL @RCCadvocate @rob_uzzo @uretericbud #IKCSNA23 @KidneyCancer @kcCURE
Last all-star expert panel at #UromigosLive discussing the mgmt of IO-refractory RCC:
-Why was #CONTACT03 negative?
-How much time should pass to rechallenge IO if so?
-#TiNivo2 - 2L/3L, prior IO, 0.89mg TiVo/Nivo vs 1.34mg Tivo, expected results?
-Role of ipi/nivo salvage?
Unraveling the efficacy of PD-1/PDL-1 re-challenge in #KidneyCancer
@DrChoueiri @DanaFarber_GU joins @CaPsurvivorship @DanaFarber in this discussion of the #CONTACT03 study on UroToday. ๐งฌ๐ฏ > https://t.co/L82uXersQm @TheLancet @montypal @AlbigesL @tompowles1 @crisuarez08
Unraveling the efficacy of PD-1/PDL-1 re-challenge in #KidneyCancer
@DrChoueiri @DanaFarber_GU joins @CaPsurvivorship @DanaFarber in this discussion of the #CONTACT03 study on UroToday. ๐งฌ๐ฏ > https://t.co/L82uXersQm @TheLancet @montypal @AlbigesL @tompowles1 @crisuarez08
You know youโve made it whenโฆ @motzermd anchors refractory talk w my discussion from #GU23 & gives us important insights on @AlbigesL #CABOPOINT & @DrChoueiri @montypal #CONTACT03 trials โ still much more to come for IO-pretreated #kidneycancer
#KCRS23 @kidneycan @KidneyCancer
GU Cancer Highlights from #ASCO23 w/@DrChoueiri
- #TALAPRO2
- #CLEAR
- #CONTACT03
- #THOR
Full Discussion:
- https://t.co/784Uu6DN6o
- Podcast https://t.co/OXHy9K3foU
#gusm @ASCO #OncTwitter #MedTwitter @HemOncFellows @TargetedOnc #MedEd @OncoAlert @IMG_Oncologists #OncEd
Unraveling the efficacy of PD-1/PDL-1 re-challenge in #KidneyCancer
@DrChoueiri @DanaFarber_GU joins @CaPsurvivorship @DanaFarber in this discussion of the #CONTACT03 study on UroToday. ๐งฌ๐ฏ > https://t.co/L82uXersQm @TheLancet @montypal @AlbigesL @tompowles1 @crisuarez08
Unraveling the efficacy of PD-1/PDL-1 re-challenge in #KidneyCancer
@DrChoueiri @DanaFarber_GU joins @CaPsurvivorship @DanaFarber in this discussion of the #CONTACT03 study on UroToday. ๐งฌ๐ฏ > https://t.co/L82uXersQm @TheLancet @montypal @AlbigesL @tompowles1 @crisuarez08
The #OncoAlertTopTweet ๐จ
Day 4โฃof #ASCO23 ๐
Tweet by our @OncoAlert faculty @montypal
@DrChoueiri at #ASCO23 of #CONTACT03 @TheLancet!
Best, @weoncologists
Flawless presentation by @DrChoueiri at #ASCO23 of #CONTACT03 results. We didnโt sleep much over the past several weeks putting this manuscript together for simultaneous pub in @TheLancet! Thank you to @katy_beckermann & @brian_rini for a terrific editorial accompanying the piece. Clearly, we need prospective data (across tumor types!) before we re-challenge w IO. Thank you to @NehaVapiwala & the @ASCO committee for highlighting our work!
Last Seen Hashtags on Sotwe
ูุฏุงุฏ_ุณูุทุงูุฉ
hoejabi
Seen from Norway
latexmaske
Seen from Germany
lightskin
Eniyah_IsRising
Seen from United States
เธเธงเธขเธเธฃเธฐ
Seen from Thailand
elsafanart
Seen from United Kingdom
momson()*** #exny()*** #nolimit()***
nolimit() +filter:native_video
Seen from United States
ุนุจุฏุงูุฑุญู
ู_ุงูุฎุถูุฑู_ูู_ููู_ู
ูุฉ
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.4M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.2M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.6M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.8M followers
KATY PERRY
@katyperry
87.4M followers
Taylor Swift
@taylorswift13
81.3M followers
Lady Gaga
@ladygaga
72.8M followers
Kim Kardashian
@kimkardashian
69.7M followers
Virat Kohli
@imvkohli
69.6M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.8M followers
The Ellen Show
@theellenshow
62.5M followers
Neymar Jr
@neymarjr
62.3M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.5M followers